Drug Profile

SAR 447537

Alternative Names: AAT-Fc; AAT-IgG-Fc; AT-292; INBRX-101; rhAAT-Fc; SAR-447537

Latest Information Update: 14 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Inhibrx
Class Recombinant fusion proteins
Mechanism of Action Alpha 1-antitrypsin replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alpha 1-antitrypsin deficiency
New Molecular Entity Yes

Highest Development Phases

Phase II Alpha 1-antitrypsin deficiency

Most Recent Events

12 Feb 2025 Sanofi plans regulatory submission for Alpha-1 antitrypsin deficiency in 2026 (Sanofi pipeline, February 2025)
23 Jan 2024 Sanofi and Inhibrx enter into an agreement for the acquisition of INBRX 101
20 Sep 2023 Company plans to meet with the US FDA following completion of ElevAATe trial

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com